Cargando…

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy

Pulmonary arterial hypertension (PAH) is a progressive disease that causes severe disability and has no cure. Over the past 20 years, a variety of treatment options have evolved for the management of PAH. With an expanded therapeutic armamentarium come more complex decisions regarding treatment opti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buckley, Mitchell S, Staib, Robin L, Wicks, Laura M, Feldman, Jeremy P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108715/ https://www.ncbi.nlm.nih.gov/pubmed/21701627 http://dx.doi.org/10.2147/DHPS.S6215

Ejemplares similares

A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension
por: Dang, Zhan-Cui, et al.
Publicado: (2019)

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis
por: Cao, Fen, et al.
Publicado: (2023)

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
por: Kataoka, Masaharu, et al.
Publicado: (2019)

Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry
por: Garcia, Agustin R., et al.
Publicado: (2023)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
por: Rahaghi, Franck F., et al.
Publicado: (2022)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease
por: Han, Bing, et al.
Publicado: (2018)

Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report
por: Bremer, Hinrich C, et al.
Publicado: (2007)

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
por: Kimura, Mai, et al.
Publicado: (2015)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
por: Butrous, Ghazwan
Publicado: (2014)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension
por: Mergia, Evanthia, et al.
Publicado: (2016)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
por: Karedath, Jithin, et al.
Publicado: (2023)

Additive Effect of Phosphodiesterase Inhibitors in Control of Pulmonary Hypertension after Congenital Cardiac Surgery in Children
por: Peiravian, Farah, et al.
Publicado: (2013)

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy
por: Wen, Jian-jun, et al.
Publicado: (2016)

Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review
por: Sanchez Palacios, Galo M., et al.
Publicado: (2020)

Phosphodiesterase 5 Attenuates the Vasodilatory Response in Renovascular Hypertension
por: Stegbauer, Johannes, et al.
Publicado: (2013)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Bell, Nicholas P, et al.
Publicado: (2010)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism
por: Sharma, Munish, et al.
Publicado: (2019)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
por: Seimetz, Michael, et al.
Publicado: (2015)

Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia
por: Nydegger, Coline, et al.
Publicado: (2018)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension
por: Dias, Ananda T, et al.
Publicado: (2014)

New Prospective Phosphodiesterase Inhibitors: Phosphorylated Oxazole Derivatives in Treatment of Hypertension
por: Nizhenkovska, Iryna V., et al.
Publicado: (2023)

Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors
por: Al-Shaiji, Tariq F., et al.
Publicado: (2009)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE)
por: Bliss, Amy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lgisasppeuro6a39rmjnckli9b